Alpine Woods Capital Investors’s Seres Therapeutics MCRB Stock Holding History

Alpine Woods Capital Investors’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-5,250	Closed	-$338K	–	272
2019 Q2	$338K	Buy	5,250 +2,250	+75%	+$214K	0.07%	218
2019 Q1	$412K	Buy	+3,000	New	+$366K	0.09%	191

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Alpine Woods Capital Investors's MCRB Position: Q3 2019 in Review

Alpine Woods Capital Investors sold out of Seres Therapeutics (MCRB) in Q3 2019, closing a stake of 5,250 shares — an estimated $338K sold.

Alpine Woods Capital Investors first reported a position in MCRB in Q1 2019 and held it in 2 quarters. The position peaked at $412K in Q1 2019. 77 funds tracked by Wall St. Rank hold MCRB as of Q3 2019.

Alpine Woods Capital Investors reported no remaining Seres Therapeutics position as of Q3 2019 after selling out during the quarter.
Alpine Woods Capital Investors sold 5,250 Seres Therapeutics shares in Q3 2019, an estimated $338K.
Alpine Woods Capital Investors first reported a position in Seres Therapeutics in Q1 2019 and held it in 2 quarters.
Alpine Woods Capital Investors's Seres Therapeutics position peaked at $412K in Q1 2019.
77 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2019.

Based on Alpine Woods Capital Investors's 13F filing for Q3 2019, filed 1 Nov 2019.